相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil
Andre de Lima Guerra Corado et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2016)
Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance
Andre Furco et al.
AIDS (2009)
Effects of Omeprazole on Plasma Levels of Raltegravir
Marian Iwamoto et al.
CLINICAL INFECTIOUS DISEASES (2009)
Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz et al.
AIDS (2008)
Resistance profile of darunavir:: Combined 24-week results from the POWER trials
Sandra de Meyer et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
Matt S. Anderson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients
Anne-Genevieve Marcelin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Marian Iwamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Lack of a significant drug interaction between raltegravir and tenofovir
Larissa A. Wenning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects
Anton L. Pozniak et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers
Monika Scholler-Gyure et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc: The first of a new class of antiretroviral agents
Rodger D. MacArthur et al.
CLINICAL INFECTIOUS DISEASES (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Martin S. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2008)
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects
Marian Iwamoto et al.
CLINICAL INFECTIOUS DISEASES (2008)
Tipranavir - A review of its use in the management of HIV infection
Jennifer S. Orman et al.
DRUGS (2008)
Powder for reconstitution of the anti-HIV-1 drug TMC278-Formulation development, stability and animal studies
Elke Van Gyseghem et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)
Maraviroc: integration of a new antiretroviral drug class into clinical practice
Linos Vandekerckhove et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation
Marian Iwamoto et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis
G. Chrysos et al.
JOURNAL OF INFECTION (2008)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean-Michel Molina et al.
LANCET (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine
Monika Scholler-Gyure et al.
PHARMACOTHERAPY (2008)
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
M. Iwamoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers
Vanitha J. Sekar et al.
THERAPEUTIC DRUG MONITORING (2007)
Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme
Kelem Kassahun et al.
DRUG METABOLISM AND DISPOSITION (2007)
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
Marta Boffito et al.
AIDS (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Adriano Lazzarin et al.
LANCET (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Jose Valdez Madruga et al.
LANCET (2007)
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:: a randomised controlled phase III trial
Jose Valdez Madruga et al.
LANCET (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet et al.
LANCET (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Darunavir - In the treatment of HIV-1 infection
Caroline Fenton et al.
DRUGS (2007)
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacovir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (vol 368, pg 476, 2006)
Joseph Eron et al.
LANCET (2006)
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks et al.
LANCET (2006)
HIV entry inhibitors: mechanisms of action and resistance pathways
V Briz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
K Andries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults
MA Noor et al.
AIDS (2004)
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
K Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
S Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
